Amgen, one of the world’s leading biotechnology companies, is teaming with Arrowhead Pharmaceuticals to bring two drugs to market to treat cardiovascular disease in a deal worth more than $50 million to start, with the potential for an additional $600 million or more in the future.

Arrowhead is based in Pasadena, California but most of its research — including work on these two drugs — is conducted in Madison, at 465 Science Drive, where the company has about 100 employees.

Read more.